At present, one of the most promising target of therapeutic intervention is TNFα, since the observation that rheumatoid arthritis patients treated with the TNFα inhibitor Etanercept have lower risk to develop AD (Chou et al., 2016). The gene discussed is TNF; the disease is rheumatoid arthritis.